Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

C-kit expression in pediatric solid tumors: a comparative immunohistochemical study.

Brandon E Smithey1, Alberto S Pappo, D Ashley Hill

  • 1Department of Pathology, University of Tennessee Medical Center, Memphis, Tennessee, USA.

The American Journal of Surgical Pathology
|March 27, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pleuropulmonary Blastoma and Diagnostic Pitfalls: A Report from the International Pleuropulmonary Blastoma/DICER1 Registry.

Archives of pathology & laboratory medicine·2026
Same author

NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

A Newborn With a Red-Brown Nasal Mass.

Pediatric dermatology·2025
Same author

Comparing Whole-Body Diffusion-weighted MRI to Conventional Imaging: Staging Pediatric Bone and Soft-Tissue Sarcomas.

Radiology. Imaging cancer·2025
Same author

ESFT13: A Phase II Study Evaluating the Addition of Window and Maintenance Therapy to a Standard Chemotherapy Backbone for the Treatment of High-Risk Ewing Sarcoma.

Cancers·2025
Same author

Acute cardiotoxicity in pediatric and adolescent patients with solid tumors treated with tyrosine kinase inhibitors.

Cancer·2025

The stem cell factor/c-kit pathway is crucial for tumor growth. This study identified specific sarcomas expressing c-kit, suggesting potential therapeutic targets for STI-571 (Gleevec) treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • The stem cell factor/c-kit pathway is implicated in the growth of various cancers.
  • STI-571 (Gleevec) is a tyrosine kinase inhibitor effective against certain cancers like gastrointestinal stromal tumors.
  • Identifying new tumors utilizing the c-kit pathway could expand therapeutic options.

Purpose of the Study:

  • To investigate the expression of c-kit in a variety of primary tumors.
  • To identify potential new cancer types that may respond to STI-571 treatment.
  • To correlate c-kit expression patterns with known responders like gastrointestinal stromal tumors.

Main Methods:

  • Immunohistochemical analysis of 151 primary tumors using anti-human c-kit (CD117) antibody.

Related Experiment Videos

  • Utilized formalin-fixed, paraffin-embedded tissue sections.
  • Employed standard avidin-biotin-peroxidase complex technique with automated staining and antigen retrieval.

    • Main Results:

    • Strong, diffuse c-kit expression was observed in synovial sarcomas, osteosarcomas, and Ewing sarcomas.
    • Less frequent strong staining was noted in neuroblastomas, Wilms' tumors, and rhabdomyosarcomas.
    • Alveolar soft part sarcomas and desmoplastic small round cell tumors showed negative staining for c-kit.

    Conclusions:

    • Synovial sarcomas, osteosarcomas, and Ewing sarcomas exhibit significant c-kit expression.
    • Tumors with strong, diffuse c-kit staining, similar to gastrointestinal stromal tumors, are potential targets for novel therapies.
    • This research supports the exploration of STI-571 or similar agents for these identified tumor types.